At a glance
ClinicalIndex Comparison RecordPhase 2Active· 18 enrolled
Drug / intervention
Ibrutinib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance
In Brief
A Phase 2 clinical trial evaluating Ibrutinib, Laboratory Biomarker Analysis, and 2 other interventions for Metastatic Melanoma and 2 related conditions. Active but no longer recruiting, targeting 18 participants across 13 sites.
Detailed Summary
This phase II trial studies how well ibrutinib works in treating patients with stage IV melanoma of the skin that has not responded to previous treatment. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
201620172018201920202021202220232024202520262027
First PostedOct 2015
Enrollment StartAug 2016
Primary CompletionFeb 2018
TodayJul 2026
Study CompletionMar 2027
First PostedOct 21, 2015
Enrollment StartAug 17, 2016
Primary CompletionFeb 10, 2018
Study CompletionMar 4, 2027
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.7 years ago
Interventions
Ibrutinibdrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Pharmacogenomic Studyother
Correlative studies
Pharmacological Studyother
Correlative studies